#None #Egret Therapeutics #Genexine #GX-P1

Egret Therapeutics and Genexine's Strategic Partnership

In a remarkable step towards advancing cancer therapies, Egret Therapeutics, a clinical-stage biotechnology company, has signed a non-binding Memorandum of Understanding (MOU) with Genexine, Inc. This agreement indicates a vital transition where Egret aims to acquire complete ownership of GX-P1, also known as EGT-101, a first-in-class PD-1 agonist.

Implications of the Acquisition

The strategic importance of securing full ownership of EGT-101 cannot be overstated. Daniel Chai, MD, the Co-Founder and CEO of Egret Therapeutics, emphasized this as a pivotal moment for the organization. By consolidating the intellectual property of the PD-1 agonist, Egret will achieve greater autonomy in the development process. This strategic move aims to streamline operations and maximize the therapeutic potential for patients suffering from acute secondary inflammation, specifically following traumatic injuries and ischemic events.

Pursuant to the MOU dated March 6, 2026, the agreement highlights a transition from a previously exclusive global license to an outright asset transfer. This transition is anticipated to grant Egret sole ownership over the licensed product, including associated intellectual property and materials, contingent upon finalizing a definitive agreement.

Strengthening Egret’s Strategic Position

Henry Park, CFO of Egret Therapeutics, noted, “This MOU represents a transformative milestone for Egret.” By evolving from a licensee to the outright owner of the PD-1 agonist, Egret is strengthening its strategic position, which will facilitate intellectual property management and enhance the flexibility necessary for pursuing strategic partnerships. Furthermore, it provides opportunities for long-term value generation which might be beneficial for shareholders and the wider patient community.

Focus on Malignant Cerebral Edema (MCE)

A focal point of Egret’s ongoing research is the treatment of Malignant Cerebral Edema (MCE), which develops following Large Vessel Occlusion Stroke (LVO). Approximately 80,000 patients in the U.S. encounter this life-threatening complication each year, which produces a dire risk of catastrophic brain swelling due to secondary inflammation. Sadly, untreated MCE leads to an alarming 80% mortality rate within a week, alongside significant neurological impairments among survivors.

Currently, treatment options for MCE are sparse and tend to focus on temporary symptom relief rather than addressing the underlying mechanisms driving the complications. With EGT-101, Egret anticipates a potent solution, as the drug is tailored to intercept the PD-1+ monocyte-driven inflammatory cascade responsible for severe cerebral swelling.

Understanding EGT-101

EGT-101 operates as a PD-L1-hyFc fusion protein intended for immune modulation post-ischemic and traumatic injuries. The design works by engaging PD-1 on circulating monocytes, promoting a shift in these maligned immune cells from an inflammatory stance to a restorative one. Such a transformative action could preserve tissue structures and enhance overall recovery outcomes, representing a significant leap in treatment approaches for secondary inflammatory damage.

Promising preclinical results have already emerged, showcasing EGT-101's capacity to diminish secondary inflammation and improve recovery in neurological and cardiovascular injury models. The innovative therapy has navigated successfully through Phase 1 trials with healthy volunteers, revealing no significant adverse effects and demonstrating favorable pharmacokinetic properties. Egret is now preparing for a Phase 1b/2a clinical trial targeting MCE, placing EGT-101 at the forefront of therapies addressing a critical need in neurology.

Egret Therapeutics' Vision

Founded on innovative research focusing on immune response modulation, Egret Therapeutics is set to redefine therapeutic possibilities for patients burdened with secondary inflammatory conditions. The organization's scientific leaders discovered that PD-1+ monocytes play a hidden yet significant role in amplifying inflammation across various traumatic and ischemic injury types, stemming the need for targeted therapies. With an expanded intellectual property portfolio and a development pipeline alert to market gaps, Egret is poised to content with a potentially lucrative target market valued at over $45 billion.

In summary, the agreement between Egret Therapeutics and Genexine marks a significant step in the fight against secondary inflammatory conditions, especially surrounding traumatic and ischemic injuries. The commitment to bringing advanced therapies like EGT-101 to patients demonstrates Egret's dedication to pioneering solutions that stand to make a real difference in medical practice and patient outcomes.